SIGA — SIGA Technologies, Inc.

SIGA Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Product Revenue: Approximately $86 million for the first nine months of 2025, including $53 million from oral TPOXX, $26 million from IV TPOXX under the BARDA contract, and $6 million from international sales.
• Q3 Performance: Product revenue for Q3 was $0.9 million, reflecting a quieter quarter following a strong Q2 with $79 million in product revenues.
• Net Income: Approximately $29 million for the nine months ended September 30, 2025, with a fully diluted income per share of $0.40. Q3 net loss was approximately $6 million, translating to a net loss per share of $0.09.
• Cash Position: Strong balance sheet with cash reserves of approximately $172 million and no debt.

2. Strategic Updates and Business Highlights:

• SIGA is focused on enhancing preparedness for smallpox outbreaks, emphasizing the importance of TPOXX as a critical medical countermeasure.
• The company has ongoing discussions with the U.S. government regarding future TPOXX procurement and development, with $27 million awarded for pediatric formulation development and IV tech transfer activities.
• Internationally, SIGA is engaging with stakeholders to expand its customer base and anticipates multiple international sales in 2026.
• The European Medicines Agency (EMA) is reviewing TPOXX for mpox treatment, with SIGA confident in its responses to EMA inquiries.

3. Forward Guidance and Outlook:

• SIGA expects to deliver $26 million in outstanding orders of IV TPOXX to the U.S. government in 2026.
• The company targets an FDA submission for the TPOXX post-exposure prophylaxis program in 2026, although timelines may be affected by the ongoing government shutdown.
• Continued engagement with the U.S. government is anticipated to maintain access to TPOXX, viewed as essential for bioterrorism preparedness.

4. Bad News, Challenges, or Points of Concern:

• The ongoing U.S. government shutdown may lead to delays in the CDC's analysis of samples for the PEP program, potentially impacting timelines.
• Q3 revenue was significantly lower than Q2, highlighting the inherent volatility in SIGA's business model.
• Increased cost of goods sold as a percentage of sales in Q3 was attributed to fixed costs related to production, which may not reflect future trends.

5. Notable Q&A Insights:

• Management indicated that operational activities related to existing government contracts have not been materially impacted by the government shutdown, although some delays may occur.
• SIGA's strong cash position (over 4x annual operating expenses) provides flexibility to navigate potential challenges.
• The company emphasized that fluctuations in quarterly revenue are typical and do not indicate a negative trend, with ongoing efforts to adapt to changing environments.

Overall, SIGA remains committed to its strategic initiatives and maintaining strong government partnerships, while also managing the challenges posed by external factors such as the government shutdown.